A phase II trial of pan-HER inhibitor Poziotinib, in patients with HER2-positive metastatic breast cancer who have received at least two prior HER2-directed regimens: The results of NOV120101-203 trial

Authors :: G.M. Kim
S.H. Kim
K.H. Lee
Joohyuk Sohn
S-A. Im
Young-Ae Park
T-Y Kim
Jihyeung Kim
S-B Kim
K-H Lee
J-Y Kim
J. Kang
Joonghyun Ahn
Hye-Suk Han
IH Park
Kyung Hwa Jung
Jong-Joon Ahn
KS Lee
Y-H. Im
Source :: Annals of Oncology. 28:v74
Publication Year :: 2017
Publisher :: Elsevier BV, 2017.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Poziotinib
Hematology
medicine.disease
Metastatic breast cancer
03 medical and health sciences
0302 clinical medicine
030220 oncology & carcinogenesis
Internal medicine
medicine
In patient
030212 general & internal medicine
business

Full Text Access

Tools